Why Servier’s $2.5bn acquisition of Day One Biopharmaceuticals could reshape the pediatric glioma treatment landscape
Servier plans a $2.5B acquisition of Day One Biopharmaceuticals to expand its rare oncology pipeline. Discover what the deal means for pediatric glioma.